AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 616168499
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (bolus and infusion equal to ketamine group)
Trial: 36126454
Drug: Afatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30 mg or 40 mg) without PPI (period A)
Trial: 36126454
Drug: Afatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30 mg or 40 mg) with 40 mg esomeprazole (period B)
Trial: 36126454
Drug: Afatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30 mg or 40 mg) three hours after esomeprazole intake (period C)
Trial: 33315169
Drug: Short-term dual
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dual antiplatelet therapy (DAPT) (at most 6 months)
Trial: 33315169
Drug: Long-term dual
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term dual antiplatelet therapy (DAPT) (at least 12 months)
Trial: 33447025
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol 100/25 μg once daily
Trial: 34662548
Drug: Sbv +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sbv + topical BC bio-curatives
Trial: 35833676
Drug: Trauma Center
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Center Trauma-Sensitive Yoga (TCTSY), 10 weekly sessions
Trial: 35833676
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT), 12 weekly sessions
Trial: 34221251
Drug: 3MDR therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3MDR therapy
Trial: 32474728
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg
Trial: 35091036
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of weight-based (15 mg/kg) vancomycin
Trial: 36032232
Drug: Taijiquan combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taijiquan combined with acupoint pressing (treatment before sleep)
Trial: 36032232
Drug: Taijiquan combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taijiquan combined with acupoint pressing (treatment after sleep)
Trial: 36032232
Drug: Taijiquan combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taijiquan combined with acupoint pressing (both treatment groups)
Trial: 35139161
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin withdrawal (placebo)
Trial: 35139161
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of intravenous immunoglobulin treatment (control)
Trial: 33141327
Drug: Group handwashing
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group handwashing facilities and daily group handwashing and toothbrushing activities
Trial: 35191268
Drug: Micro needle
RxNorm normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro needle knife therapy
Trial: 35191268
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug (Merislon, 6 mg, 3 times a day for 2 weeks)
Trial: 35123457
Drug: Fixed-dose inhaled
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose inhaled corticosteroids (ICS) as control
Trial: 35123457
Drug: Taper and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper and subsequently stop ICS
Trial: 35332685
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) additional over inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP) for 12 weeks (n = 30)
Trial: 34365905
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GOS (10-15 grams/day)
Trial: 34365905
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GOS (15-20 grams/day)
Trial: 34365905
Drug: GOS (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS (both doses)
Trial: 35670987
Drug: Triggered escalating
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triggered escalating real‐time adherence (TERA) intervention with remote coaching, electronic dose monitoring (EDM), and outreach for missed/delayed doses
Trial: 32503806
Drug: Simplified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified treatment schedules, telemedicine facilitation, decreased data collection requirements
Trial: 33720997
Drug: Daily SMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily SMS reminders about insulin injections
Trial: 32709172
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided Erector Spinae Plane (ESP) block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000)
Trial: 34817667
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication reconciliation at hospital admission
Trial: 33486475
Drug: Standard hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydration (0.9% saline at 0.5 mL/(kg·h))
Trial: 32105310
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin (FC) <250 µg/g
Trial: 32105310
Drug: CRP <5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP <5 mg/L
Trial: 32105310
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin <250 µg/g, CRP <5 mg/L, and CDAI <150
Trial: 35313276
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of N3-rich foods and supplement compliance
Trial: 33814320
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow therapy (NHFT)
Trial: 34551998
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LD‐MTX) 15-20 mg/week
Trial: 34551998
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LD‐MTX)
Trial: 32565333
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg taken 1 hour before treatment
Trial: 32565333
Drug: Nonibuprofen (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonibuprofen (no analgesics taken before treatment)
Trial: 32565333
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (4 patients undergoing endodontic therapy for prosthodontic reasons, no analgesics)
Trial: 33314332
Drug: Microtextured implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtextured implants with a 3.6mm-long internal-connection machined collar
Trial: 33314332
Drug: Machined implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined implants with a 1.2mm-long external-connection machined collar
Trial: 33314332
Drug: Microtextured implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microtextured implants with a 1.2mm-long external-connection machined collar
Trial: 33314332
Drug: Internal-connection microtextured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal-connection microtextured implants
Trial: 33314332
Drug: External-connection microtextured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External-connection microtextured implants
Trial: 33314332
Drug: All implant
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implant types
Trial: 32381373
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (14 mg)
Trial: 33293295
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (monthly, individual CHV home visits)
Trial: 32214373
Drug: Personalized metabolism-informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized metabolism-informed care (MIC)
Trial: 35596182
Drug: Olaparib as
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib as maintenance therapy
Trial: 35596182
Drug: Newly derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly derived reference values for treatment-naïve mPC patients
Trial: 34530495
Drug: Individual reminiscence
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual reminiscence therapy for 8 weeks during home visits (once a week)
Trial: 32067533
Drug: High-dose folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folic acid (4.0-5.1 mg daily)
Trial: 35410783
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative laxatives
Trial: 33663414
Drug: Monthly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sessions regarding physical activity and health-related topics for 6 months (Control)
Trial: 35379537
Drug: Case Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case Management with Problem-Solving Therapy (CM-PST)
Trial: 32171064
Drug: Maintenance budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance budesonide (200 μg twice per day) plus as-needed salbutamol (two inhalations of 100 μg)
Trial: 32171064
Drug: As-needed salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As-needed salbutamol (two inhalations of 100 μg)
Trial: 32171064
Drug: As-needed budesonide-formoterol
RxNorm normalized name: budesonide / formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed budesonide-formoterol (one inhalation of 200 μg budesonide and 6μg formoterol)
Trial: 35074887
Drug: Group-administered recovery
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-administered recovery programme (3 sessions, 2 weeks apart)
Trial: 33038833
Drug: DHA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (50 mg/Kg/day)
Trial: 32871950
Drug: Conbercept 6-monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conbercept 6-monthly loading dose injection and PRN (6+PRN)
Trial: 32871950
Drug: Conbercept 3-monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conbercept 3-monthly loading dose injection and PRN (3+PRN)
Trial: 35502861
Drug: Cold Acclimation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold Acclimation (CA) - immersion to the chest in 14°C water for ≥120 min daily over a 5-day period
Trial: 34391917
Drug: Lidocaine (L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (L group)
Trial: 35460249
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) supplementation (weekly 50,000 IU for 4 weeks followed by daily 2000 IU until 1 year)
Trial: 33763741
Drug: Continuous local
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous local anaesthetic wound infusion
Trial: 32144911
Drug: Acupoint thread-embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread-embedding therapy at 7-day intervals (Treatment Group 1)
Trial: 32144911
Drug: Acupoint thread-embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint thread-embedding therapy at 14-day intervals (Treatment Group 2)
Trial: 32144911
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between Treatment Group 1 and Treatment Group 2
Trial: 34329456
Drug: Recreational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational therapy program (3 sessions a week for 2 weeks)
Trial: 34329456
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily activities
Trial: 33034357
Drug: High myopic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High myopic treatment with LASIK
Trial: 33684015
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (upper limb fascial therapy, 50 min weekly session for three weeks)
Trial: 32415802
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg daily for 12 weeks
Trial: 35533200
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of the noradrenaline reuptake inhibitor atomoxetine
Trial: 33131470
Drug: Proactive anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive anti-inflammatory therapy combined with anticoagulation
Trial: 33128492
Drug: Propranolol 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 1% cream
Trial: 33128492
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% cream
Trial: 34864993
Drug: Endometrial scratch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial scratch prior to the second IVF/ICSI treatment
Trial: 32931708
Drug: bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bovine lactoferrin (bLF) 200 mg·(kg body mass)‐1·day‐1
Trial: 35921506
Drug: Pramipexole (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.75 mg twice daily, n = 100)
Trial: 33423364
Drug: Fludora® Fusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludora® Fusion 562.5 WP-SB (target dose 225 mg AI/m2)
Trial: 33423364
Drug: Clothianidin 70
RxNorm normalized name: CLOTHIANIDIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clothianidin 70 WG (target dose 200 mg AI/m2)
Trial: 33423364
Drug: K-Othrine 250
RxNorm normalized name: potassium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Othrine 250 WG (deltamethrin, target dose 25 mg AI/m2)
Trial: 33423364
Drug: Ficam VC
RxNorm normalized name: Zicam Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ficam VC 80 WP-SB (bendiocarb, target dose 400 mg AI/m2)
Trial: 35291435
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with vitamin E (20 mg atorvastatin and 400 IU vitamin E daily for 12 weeks)
Trial: 35291435
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with placebo (20 mg atorvastatin daily for 12 weeks)
Trial: 35291435
Drug: Atorvastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin with vitamin E
Trial: 32146550
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg three times daily (tds) in combination with carboplatin/paclitaxel
Trial: 32146550
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg tds
Trial: 34417416
Drug: Supervised group‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group‐based multicomponent exercise program intervention with oral nutritional supplementation (OEP+N)
Trial: 33988924
Drug: Paliperidone Palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone Palmitate once-monthly (PP1M)
Trial: 33988924
Drug: Oral Antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Antipsychotics (OAPs)
Trial: 32894625
Drug: Standard eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard eradication triple therapy
Trial: 35849455
Drug: LNG 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG 1.5 mg
Trial: 35849455
Drug: LNG 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNG 3.0 mg
Trial: 32643500
Drug: Standard G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard G-CSF administration (24 hours after chemotherapy)
Trial: 32643500
Drug: Delayed G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed G-CSF administration (on the day ANC dropped below 1,000/mm3)
Trial: 32643500
Drug: Delayed G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed G-CSF administration
Trial: 32643500
Drug: Standard G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard G-CSF administration
Trial: 34684661
Drug: OMEGA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMEGA group (20 mL daily dose of dietary formula containing omega-3 and omega-6 PUFAs, vitamin A, vitamin E, and γ-tocopherol)
Trial: 34684661
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (20 mL placebo containing virgin olive oil)
Trial: 35843540
Drug: Wheat germ
RxNorm normalized name: Wheat Germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat germ (40 g)
Trial: 32737004
Drug: NEXIRI (Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEXIRI (Irinotecan 120-180 mg/m2 intravenous on days 1 and 15 plus oral Sorafenib 400 mg twice a day)
Trial: 32737004
Drug: IRI (Irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRI (Irinotecan 180 mg/m2)
Trial: 33480852
Drug: Smartphone app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone app-based intervention used for 28 days offering daily activities based on 10 recommendations to promote positive mental health.
Trial: 36746171
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg every 4 weeks
Trial: 34763441
Drug: Manual injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual injection of contrast (N group, n=50)
Trial: 34763441
Drug: Gravity drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gravity drip administration of contrast media (O group, n=50)
Trial: 35366928
Drug: Ludangshen oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ludangshen oral liquid
Trial: 35608396
Drug: PAD bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAD bundle (pain monitoring and management, light sedation and daily awakening, early mobility, sleep promotion, and delirium monitoring)
Trial: 34280355
Drug: Icotinib 125
RxNorm normalized name: niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib 125 mg thrice daily for 2 years
Trial: 34280355
Drug: Chemotherapy (vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vinorelbine and cisplatin or pemetrexed and cisplatin)
Trial: 32852646
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.03% ointment applied once daily for 2–6 months
Trial: 33933667
Drug: QUIT intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUIT intervention (cognitive behavioral therapy-based, individual weekly counseling sessions targeting anxiety and depressive symptoms)
Trial: 33933667
Drug: Time-Matched Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-Matched Control (TMC) (cognitive behavioral therapy-based, individual weekly counseling sessions)
Trial: 32074412
Drug: Antipsychotics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics treatment
Trial: 36333896
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/day) for 14 days
Trial: 33285733
Drug: Danlou tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danlou tablet (1.5 mg a time, 3 times daily for 28 days)
Trial: 34961754
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise intervention during chemotherapy (n = 173)
Trial: 32808656
Drug: Sparse additive
RxNorm normalized name: sparsentan
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparse additive model for treatment effect modification